CCM
GTBP icon

Conway Capital Management’s GT Biopharma GTBP Stock Holding History

Conway Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-683
Closed -$318K – 75
2021
Q2 		$318K Buy
683
+50
+8% +$20.8K 0.22% 53
2021
Q1 		$130K Buy
+633
New +$111K 0.1% 71

Other funds holding GTBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

Conway Capital Management's GTBP Position: Q3 2021 in Review

Conway Capital Management sold out of GT Biopharma (GTBP) in Q3 2021, closing a stake of 683 shares — an estimated $318K sold.

Conway Capital Management first reported a position in GTBP in Q1 2021 and held it in 2 quarters. The position peaked at $318K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q3 2021.

  • Conway Capital Management reported no remaining GT Biopharma position as of Q3 2021 after selling out during the quarter.
  • Conway Capital Management sold 683 GT Biopharma shares in Q3 2021, an estimated $318K.
  • Conway Capital Management first reported a position in GT Biopharma in Q1 2021 and held it in 2 quarters.
  • Conway Capital Management's GT Biopharma position peaked at $318K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2021.

Based on Conway Capital Management's 13F filing for Q3 2021, filed 3 Dec 2024.